Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Docetaxel + SGT-53 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Docetaxel | Taxotere | RP56976 | Antimicrotubule Agent 14 | Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (PMID: 32496783, PMID: 32366558). |
SGT-53 | transferrin receptor-targeted liposomal p53 cDNA|Synerlip p53 | p53 Gene Therapy 4 | SGT-53 is a cationic liposomal complex that is linked to an antibody targeting the transferrin receptor (Tff) and contains wild-type Tp53 plasmid, thereby delivering wild-type Tp53 to tumor cells expressing Tff and potentially restoring wild-type Tp53 activity (PMID: 23470564, PMID: 27357628, PMID: 31241175) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|